Your browser version may not work well with NCBI's Web applications. More information here...
1: Trends Microbiol. 2002;10(10 Suppl):S27-31.Click here to read Links

Structural proteomics: the potential of high-throughput structure determination.

Schmid MB.

Affinium Pharmaceuticals, 100 University Avenue, Toronto, Ontario, Canada. mschmid@afnm.com

The pharmaceutical industry has embraced genomics as a means to identify new biological targets for target-based drug discovery approaches. Now, genomics is driving a substantial effort in protein structure determination and structure prediction. These structures will provide the opportunity to undertake structure-guided drug discovery programs in the search for new classes of broad-spectrum antibiotics. In addition, these structures could provide structure-based criteria to prioritize certain targets for focused drug discovery programs.

PMID: 12377565 [PubMed - indexed for MEDLINE]